Payment overview · 2025
General Payments
$396.21
16 reported records · 10 companies
Healthcare provider profile · identity verified
Surendra Sugrim, MD
Allopathic & Osteopathic Physicians|Family Medicine · SOUTH RICHMOND HILL, NY · NPI 1033341185
Verified facts
What the public records show
CMS Open Payments records show Surendra Sugrim, MD received $396.21 in general payments during 2025 across 16 reported records.
Astellas Pharma US Inc accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $89.69 | 22.6% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $70.78 | 17.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.00 | 11.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.32 | 11.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.98 | 9.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.70 | 7.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.71 | 5.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.37 | 4.9% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17.88 | 4.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.78 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $396.21 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $89.69 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $70.78 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $46.00 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.98 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.98 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.98 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 79 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
70 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 648 | 199 |
| Atorvastatin Calcium | Atorvastatin Calcium | 605 | 182 |
| Losartan Potassium | Losartan Potassium | 507 | 157 |
| Metoprolol Succinate | Metoprolol Succinate | 468 | 151 |
| Simvastatin | Simvastatin | 435 | 126 |
| Metformin Hcl | Metformin Hcl | 413 | 126 |
| Omeprazole | Omeprazole | 362 | 105 |
| Diclofenac Sodium | Diclofenac Sodium | 333 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 315 | 108 |
| Glipizide | Glipizide | 292 | 77 |
| Gabapentin | Gabapentin | 290 | 92 |
| Furosemide | Furosemide | 271 | 95 |
| Atenolol | Atenolol | 224 | 63 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 215 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 205 | 67 |
| Lisinopril | Lisinopril | 198 | 60 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 183 | 52 |
| Famotidine | Famotidine | 179 | 59 |
| Ezetimibe | Ezetimibe | 169 | 61 |
| Januvia | Sitagliptin Phosphate | 167 | 44 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 166 | 60 |
| Metformin Hcl Er | Metformin Hcl | 140 | 45 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 136 | 33 |
| Tradjenta | Linagliptin | 134 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 133 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 130 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 47 |
| Meclizine Hcl | Meclizine Hcl | 117 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 36 |
| Fenofibrate | Fenofibrate Nanocrystallized | 103 | 32 |
| Glipizide Er | Glipizide | 103 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 102 | 30 |
| Valsartan | Valsartan | 100 | 26 |
| Farxiga | Dapagliflozin Propanediol | 96 | 28 |
| Azithromycin | Azithromycin | 95 | 84 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 89 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 27 |
| Clobetasol Propionate | Clobetasol Propionate | 84 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 36 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 82 | 35 |
| Jardiance | Empagliflozin | 79 | 24 |
| Linzess | Linaclotide | 70 | 26 |
| Glimepiride | Glimepiride | 66 | 19 |
| Montelukast Sodium | Montelukast Sodium | 65 | 15 |
| Ramipril | Ramipril | 63 | 18 |
| Novolog Flexpen | Insulin Aspart | 62 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 18 |
| Single Use Swab | Alcohol Antiseptic Pads | 60 | 26 |
| Enalapril Maleate | Enalapril Maleate | 58 | 15 |
| Allopurinol | Allopurinol | 57 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 20 |
| Fenofibrate | Fenofibrate,micronized | 50 | 13 |
| Carvedilol | Carvedilol | 46 | 19 |
| Eliquis | Apixaban | 45 | 15 |
| Ammonium Lactate | Ammonium Lactate | 44 | 19 |
| Acarbose | Acarbose | 43 | 14 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 43 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 14 |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 16 |
| Nifedipine Er | Nifedipine | 41 | 15 |
| Finasteride | Finasteride | 40 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 32 |
| Hydrocortisone | Hydrocortisone | 36 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 11 |
| Promethazine Hcl | Promethazine Hcl | 34 | 17 |
| Celecoxib | Celecoxib | 33 | 15 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 31 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | 13 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Clonidine Hcl | Clonidine Hcl | 26 | 11 |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 13 |
| Terconazole | Terconazole | 26 | 12 |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 22 |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 22 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 19 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 19 | 12 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $396.21 · 16 records | Astellas Pharma US Inc | ABRYSVO, ACCRUFER, AREXVY, COMIRNATY, CREON, ELYXYB - CELECOXIB, JARDIANCE, LINZESS, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Veozah, ZORYVE, ZTLido | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error